Abstract
It is unclear whether the survival difference observed between glioblastoma (GBM), giant cell glioblastoma (gcGBM), and gliosarcoma (GSM) patients is due to differences in tumor histology, patient demographics, and/or treatment regimens. The USA National Cancer Database was utilized to evaluate patients diagnosed with GBM, gcGBM, and GSM between 1998 and 2011. Kaplan-Meier survival estimates and Cox proportional hazards models were utilized to estimate overall survival. A cohort of 69,935 patients was analyzed; 67,509 (96.5%) of these patients had GBM, 592 (0.9%) gcGBM, and 1834 (2.6%) GSM. The median age for GBM and GSM patients was 61 versus 56 years for gcGBM (p < 0.0001). Higher extent of resection (p < 0.0001) and radiation (p = 0.001) were observed in gcGBM patients compared to other histologies. Multivariate analysis showed that gcGBM patients had a 20% reduction in the hazards of mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.69-0.93) compared to GBM, while GSM patients trended towards higher hazards of mortality (HR 1.04, 95% CI 0.96-1.12) than the GBM cohort. Previous studies have suggested a disparity in the survival of patients with GBM tumors and their histological variants. Using a large cohort of patients treated at hospitals nationwide, this study found a 20% reduction in the hazards of mortality in gcGBM patients compared to GBM. Similarly, gcGBM patients had a 24% reduction in the hazards of mortality compared to the GSM cohort. GSM patients had a 3% increase in the hazards of mortality compared to GBM.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1709-1713 |
| Number of pages | 5 |
| Journal | Journal of Clinical Neuroscience |
| Volume | 21 |
| Issue number | 10 |
| DOIs | |
| State | Published - Jan 1 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- Chemotherapy
- Giant cell glioblastoma
- Glioblastoma
- Gliosarcoma
- Overall survival
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
- Physiology (medical)
- Medicine(all)
Cite this
Treatment and survival of patients harboring histological variants of glioblastoma. / Ortega, Alicia; Nuno, Miriam A; Walia, Sartaaj; Mukherjee, Debraj; Black, Keith L.; Patil, Chirag G.
In: Journal of Clinical Neuroscience, Vol. 21, No. 10, 01.01.2014, p. 1709-1713.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment and survival of patients harboring histological variants of glioblastoma
AU - Ortega, Alicia
AU - Nuno, Miriam A
AU - Walia, Sartaaj
AU - Mukherjee, Debraj
AU - Black, Keith L.
AU - Patil, Chirag G.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - It is unclear whether the survival difference observed between glioblastoma (GBM), giant cell glioblastoma (gcGBM), and gliosarcoma (GSM) patients is due to differences in tumor histology, patient demographics, and/or treatment regimens. The USA National Cancer Database was utilized to evaluate patients diagnosed with GBM, gcGBM, and GSM between 1998 and 2011. Kaplan-Meier survival estimates and Cox proportional hazards models were utilized to estimate overall survival. A cohort of 69,935 patients was analyzed; 67,509 (96.5%) of these patients had GBM, 592 (0.9%) gcGBM, and 1834 (2.6%) GSM. The median age for GBM and GSM patients was 61 versus 56 years for gcGBM (p < 0.0001). Higher extent of resection (p < 0.0001) and radiation (p = 0.001) were observed in gcGBM patients compared to other histologies. Multivariate analysis showed that gcGBM patients had a 20% reduction in the hazards of mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.69-0.93) compared to GBM, while GSM patients trended towards higher hazards of mortality (HR 1.04, 95% CI 0.96-1.12) than the GBM cohort. Previous studies have suggested a disparity in the survival of patients with GBM tumors and their histological variants. Using a large cohort of patients treated at hospitals nationwide, this study found a 20% reduction in the hazards of mortality in gcGBM patients compared to GBM. Similarly, gcGBM patients had a 24% reduction in the hazards of mortality compared to the GSM cohort. GSM patients had a 3% increase in the hazards of mortality compared to GBM.
AB - It is unclear whether the survival difference observed between glioblastoma (GBM), giant cell glioblastoma (gcGBM), and gliosarcoma (GSM) patients is due to differences in tumor histology, patient demographics, and/or treatment regimens. The USA National Cancer Database was utilized to evaluate patients diagnosed with GBM, gcGBM, and GSM between 1998 and 2011. Kaplan-Meier survival estimates and Cox proportional hazards models were utilized to estimate overall survival. A cohort of 69,935 patients was analyzed; 67,509 (96.5%) of these patients had GBM, 592 (0.9%) gcGBM, and 1834 (2.6%) GSM. The median age for GBM and GSM patients was 61 versus 56 years for gcGBM (p < 0.0001). Higher extent of resection (p < 0.0001) and radiation (p = 0.001) were observed in gcGBM patients compared to other histologies. Multivariate analysis showed that gcGBM patients had a 20% reduction in the hazards of mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.69-0.93) compared to GBM, while GSM patients trended towards higher hazards of mortality (HR 1.04, 95% CI 0.96-1.12) than the GBM cohort. Previous studies have suggested a disparity in the survival of patients with GBM tumors and their histological variants. Using a large cohort of patients treated at hospitals nationwide, this study found a 20% reduction in the hazards of mortality in gcGBM patients compared to GBM. Similarly, gcGBM patients had a 24% reduction in the hazards of mortality compared to the GSM cohort. GSM patients had a 3% increase in the hazards of mortality compared to GBM.
KW - Chemotherapy
KW - Giant cell glioblastoma
KW - Glioblastoma
KW - Gliosarcoma
KW - Overall survival
UR - http://www.scopus.com/inward/record.url?scp=84908499578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908499578&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2014.05.003
DO - 10.1016/j.jocn.2014.05.003
M3 - Article
C2 - 24980627
AN - SCOPUS:84908499578
VL - 21
SP - 1709
EP - 1713
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
SN - 0967-5868
IS - 10
ER -